Intrexon Corporation (NYSE:XON) COO Andrew J. Last purchased 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were purchased at an average price of $19.99 per share, for a total transaction of $39,980.00. Following the purchase, the chief operating officer now directly owns 2,000 shares in the company, valued at $39,980. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of Intrexon Corporation (NYSE XON) traded up 0.05% on Thursday, hitting $18.22. The company’s stock had a trading volume of 311,925 shares. Intrexon Corporation has a 1-year low of $17.70 and a 1-year high of $32.90. The company has a 50 day moving average of $22.37 and a 200 day moving average of $21.89. The firm’s market cap is $2.20 billion.
Intrexon Corporation (NYSE:XON) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. The business had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.42) EPS. Equities analysts forecast that Intrexon Corporation will post ($0.87) EPS for the current year.
A number of research analysts recently issued reports on XON shares. Zacks Investment Research upgraded Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Tuesday, May 2nd. BidaskClub upgraded Intrexon Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Finally, Northland Securities set a $30.00 target price on Intrexon Corporation and gave the company a “buy” rating in a research note on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Intrexon Corporation currently has an average rating of “Hold” and an average price target of $37.60.
Hedge funds have recently made changes to their positions in the company. CWM LLC boosted its stake in shares of Intrexon Corporation by 9,455.4% in the first quarter. CWM LLC now owns 35,546 shares of the biotechnology company’s stock worth $705,000 after buying an additional 35,174 shares during the last quarter. Private Advisor Group LLC boosted its stake in shares of Intrexon Corporation by 18.6% in the first quarter. Private Advisor Group LLC now owns 35,502 shares of the biotechnology company’s stock worth $672,000 after buying an additional 5,556 shares during the last quarter. Capital Fund Management S.A. boosted its stake in shares of Intrexon Corporation by 40.9% in the first quarter. Capital Fund Management S.A. now owns 127,798 shares of the biotechnology company’s stock worth $2,533,000 after buying an additional 37,098 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Intrexon Corporation by 60.0% in the first quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock worth $2,862,000 after buying an additional 54,179 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Intrexon Corporation by 670.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 83,514 shares of the biotechnology company’s stock worth $2,029,000 after buying an additional 72,675 shares during the last quarter. Institutional investors and hedge funds own 84.52% of the company’s stock.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.